Bambusa Eyes $134.9 Million From Nasdaq IPO At $15-$17 Range, With Going-Concern Warning Intact
The Boston antibody developer proposes selling 9,375,000 shares while its cash fell to about $57.2 million at September 30.
Bambusa Therapeutics, a clinical-stage Boston company developing long-acting bispecific antibodies for immune and inflammatory diseases, set a proposed price range of $15.00 to $17.00 a share for its Nasdaq IPO in an amended registration statement filed Monday. The same document puts its cash at about $57.2 million on September 30 and keeps management's warning of substantial doubt about continuing as a going concern.
Terms of the proposed offering
Bambusa proposes to sell 9,375,000 shares and has applied to list on the Nasdaq Global Select Market under the symbol BBTX. Underwriters hold a 30-day option to buy up to 1,406,250 more shares. BofA Securities, UBS, Evercore ISI and Cantor are the listed underwriters.
At the $16.00 midpoint, the company estimates net proceeds of about $134.9 million, or about $155.8 million if the extra shares are sold in full. About 49,761,875 shares would be outstanding afterward, or 51,168,125 with the option exercised. A 1.54485-for-1 forward stock split took effect on October 23, and the share counts reflect it.
The company says 3.5% of the shares are reserved for directors, officers, employees and others tied to it.
Cash is shrinking before the money arrives
Preliminary, unaudited figures show about $57.2 million in cash, equivalents and marketable securities at September 30, versus $71.5 million at June 30. The company says that amount is not expected to fund operations for at least 12 months, so substantial doubt remains about its ability to continue as a going concern, meaning the company may not be able to keep operating.
Bambusa lost $22.4 million in the first half of 2026, compared with $14.7 million a year earlier, and has an accumulated deficit of $77.2 million. It says the IPO proceeds plus existing cash should fund operations into late 2028, and that it will still need substantial additional capital.
Where the money would go
About $90.0 million is earmarked for BBT001, including a planned mid-stage atopic dermatitis trial, and about $40.0 million for BBT002, including a planned respiratory trial. The remainder would go to two preclinical candidates, BBT003 and BBT004, and general corporate purposes.
Bambusa was incorporated in March 2024 and built its lead drugs on assets acquired from BioNTech's Zhuhai unit. It says it has raised $136.1 million in private financings through June 30. In July it reported positive early results for BBT001 in atopic dermatitis, and it expects more readouts through the first half of 2027.
The company says the IPO's closing is contingent on the Nasdaq listing, and the final price will be set only after the registration becomes effective.
Sources
- S-1/A — Bambusa Therapeutics, Inc. — SEC EDGAR